Literature DB >> 33456151

Diffuse exanthematous drug eruption associated with intravenous immunoglobulin.

Anish Paudel1, Sijan Basnet1, Biswaraj Tharu2, Nidrit Bohra1.   

Abstract

Diffuse exanthematous drug eruption due to intravenous immunoglobulin (IVIg) is a rare adverse event reported only in case reports. We present a case of a 71-year-old woman with a diffuse maculopapular rash 5 days after receiving an IVIg infusion for treatment of chronic inflammatory demyelinating polyneuropathy. She was managed conservatively with antihistamines; she was already receiving prednisone 25 mg daily as part of treatment for the neuropathy. The rash resolved over 2 weeks.
Copyright © 2020 Baylor University Medical Center.

Entities:  

Keywords:  Adverse event; exanthematous drug eruption; intravenous immunoglobulin

Year:  2020        PMID: 33456151      PMCID: PMC7785170          DOI: 10.1080/08998280.2020.1805672

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  3 in total

1.  Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.

Authors:  Gianluca Vecchietti; Katrin Kerl; Christa Prins; Gürkan Kaya; Jean-Hilaire Saurat; Lars E French
Journal:  Arch Dermatol       Date:  2006-02

2.  Significant dermatological side effects of intravenous immunoglobulin.

Authors:  Carrie B Hurelbrink; Judith M Spies; Con Yiannikas
Journal:  J Clin Neurosci       Date:  2013-05-07       Impact factor: 1.961

3.  Dyshidrotic eczema associated with the use of IVIg.

Authors:  Dilcan Kotan; Teoman Erdem; Bilgehan Atilgan Acar; Ayhan Boluk
Journal:  BMJ Case Rep       Date:  2013-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.